We're in complete agreement. A sustained price above $5 IMHO will require sales, perhaps not yet reported revenue, but the fact that product sales are occurring. The price will be sustained, and will grow once revenue is shown to be growing over each quarter.

The other thing which I believe could greatly influence share price is anecdotal reports of efficacy. When people start telling stories of improvement in their psoriasis, or other skin diseases, that news could be huge. If one of the networks picked up on someones story and featured the drug in a story on the news, the stock could go crazy. Of course the key is getting the cream out there, and seeing what it does. I believe the company knows it will be effective, but officially it has not yet been used on patients with the condition, only in safety trials of people who are healthy.

Gary